Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.

doi:10.1158/2326-6066.CIR-15-0156

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.

Cancer immunology research - 2 Sept 2016

Theurich Sebastian, Rothschild Sacha I, Hoffmann Michael, Fabri Mario, Sommer Andrea, Garcia-Marquez Maria, Thelen Martin, Schill Catherine, Merki Ramona, Schmid Thomas, Koeberle Dieter, Zippelius Alfred, Baues Christian, Mauch Cornelia, Tigges Christian, Kreuter Alexander, Borggrefe Jan, von Bergwelt-Baildon Michael, Schlaak Max

Abstract excerpt

Immune checkpoint inhibition with ipilimumab has revolutionized cancer immunotherapy and significantly improved outcomes of patients with advanced malignant melanoma. Local peripheral treatments (LPT), such as radiotherapy or electrochemotherapy, have been shown to modulate systemic immune responses, and preliminary data have raised the hypothesis that the combination of LPT with systemic immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Ipilimumab

Share to Kaplan-Meier Estimate

Share to Melanoma

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed

Identifiers

PMID: 27466265
DOI: 10.1158/2326-6066.CIR-15-0156

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.PMID 27466265Read ↗

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisSemantic proximity Read ↗

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Semantic proximity Read ↗

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Semantic proximity Read ↗

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.Semantic proximity Read ↗

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.Semantic proximity Read ↗

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read ↗

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudySemantic proximity Read ↗

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced MelanomaSemantic proximity Read ↗

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.Semantic proximity Read ↗

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.Semantic proximity Read ↗

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.Semantic proximity Read ↗

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.